Review
Pharmacology & Pharmacy
Chen Chen, Yuqi Zhang, Zhaowei Chen, Huanghao Yang, Zhen Gu
Summary: Using natural cells as drug carriers has become a hot topic in recent years due to their biocompatibility and dynamic properties. Instead of focusing on what cells display, attention is now shifting towards how cells change, including surface protein patterns, morphologies, and in-situ generation of therapeutics, to develop advanced drug delivery systems.
ADVANCED DRUG DELIVERY REVIEWS
(2021)
Review
Biochemistry & Molecular Biology
Nicholas McNamee, Ines Pires da Silva, Adnan Nagrial, Bo Gao
Summary: Small-cell lung cancer (SCLC) is an aggressive disease with limited treatment options and poor survival rates. While there have been significant advancements in the treatment of non-small cell lung cancer (NSCLC), SCLC has not seen the same level of progress. This is due, in part, to the complex and heterogeneous nature of SCLC tumors. This review explores the current treatment paradigm of SCLC, recent advances in immunotherapy, challenges in identifying predictive biomarkers, and potential future directions in SCLC treatment research.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Multidisciplinary Sciences
Lei Jiang, Sensen Zhou, Xiaoke Zhang, Cheng Li, Shilu Ji, Hui Mao, Xiqun Jiang
Summary: Mitochondria are key targets for photothermal and photodynamic treatment for cancer, but delivery of therapeutics to these organelles remains a challenge. In this study, authors developed a mitochondrial targeted liposomal delivery platform using a dendritic peptide moiety as a mitochondria targeting moiety and demonstrated its targeting and antitumour efficacy in a mouse model of breast cancer.
NATURE COMMUNICATIONS
(2021)
Review
Pharmacology & Pharmacy
Yanxia Xiao, Pu Liu, Jie Wei, Xin Zhang, Jun Guo, Yajun Lin
Summary: The high morbidity and mortality of non-small cell lung cancer pose significant health threats. However, with the identification of carcinogenic drivers and the use of targeted drugs, the prognosis for patients has greatly improved. Nonetheless, the unknown carcinogenic drivers and the issue of drug resistance in targeting therapy still hinder effective treatment. This review discusses the mechanisms of targeted-drug resistance and newly identified targets, highlighting the importance of research in driving individualized treatment for non-small cell lung cancer.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Jiajia Wu, Zhenghong Lin
Summary: Precision medicine has expanded treatment options for NSCLC patients through targeted therapy based on genetic and epigenetic cues. Antibodies and inhibitors that target critical gene-mediated signaling pathways have improved patient prognosis. However, resistance due to genetic alterations poses significant challenges in the treatment of metastatic NSCLC patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Immunology
Serena De Matteis, Michele Dicataldo, Beatrice Casadei, Gianluca Storci, Noemi Laprovitera, Mario Arpinati, Enrico Maffini, Pietro Cortelli, Maria Guarino, Francesca Vaglio, Maria Naddeo, Barbara Sinigaglia, Luca Zazzeroni, Serafina Guadagnuolo, Enrica Tomassini, Salvatore Nicola Bertuccio, Daria Messelodi, Manuela Ferracin, Massimiliano Bonafe, Pier Luigi Zinzani, Francesca Bonifazi
Summary: Inflammatory complications, such as ICANS, can affect the infusion of CAR T cells in patients with R/R-BCL. This study found that a lower percentage of CD3(+)CD8(+) lymphocytes and higher levels of CRP were associated with ICANS. Additionally, ICANS patients had an increase in senescent CD8(+) T cells and M-MDSC, as well as elevated levels of EVs carrying myeloid markers and cytokines.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Tulasigeri M. M. Totiger, Anirban Ghoshal, Jenna Zabroski, Anya Sondhi, Saanvi Bucha, Jacob Jahn, Yangbo Feng, Justin Taylor
Summary: Therapeutic developments for acute myeloid leukemia (AML) have been ongoing for fifty years, resulting in multiple approved targeted therapies. However, there is still a need for molecular treatments that can provide long-term remissions and cure for this heterogeneous disease. The development of small molecule drugs targeting sub-types of AML has been hindered by drug resistance, but combination therapies like venetoclax and azacitidine have shown improved response rates compared to chemotherapy. Despite the complexity of AML, there is a demand for therapies that target specific abnormalities and eliminate leukemia-initiating cells.
Article
Chemistry, Multidisciplinary
Mingyu Chen, Sarun Juengpanich, Shijie Li, Win Topatana, Ziyi Lu, Qiang Zheng, Jiasheng Cao, Jiahao Hu, Esther Chan, Lidan Hou, Jiang Chen, Fang Chen, Yu Liu, Sukanda Jiansirisomboon, Zhen Gu, Suparat Tongpeng, Xiujun Cai
Summary: This study reports on a targeted therapy for gallbladder cancer using pH-responsive nanoparticles encapsulating bortezomib and mediated by estrogen-induced endocytosis. The treatment effectively inhibits proteasomes and induces apoptosis under tumor microenvironment and laser irradiation.
Review
Pharmacology & Pharmacy
Wenliang Liu, Siying Ren, Ying Xiao, Lulu Yang, Chao Zeng, Yan Hu
Summary: This mini-review summarizes the current evidence and potential clinical strategies of neoadjuvant EGFR-TKIs targeted therapy for resectable EGFR-mutated NSCLC.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Oncology
Andreas Domen, Christophe Deben, Jasper Verswyvel, Tal Flieswasser, Hans Prenen, Marc Peeters, Filip Lardon, An Wouters
Summary: Cellular senescence is a mechanism in which cells enter a state of stable cell-cycle arrest with secretory features in response to cellular stress. It has been historically seen as a protective mechanism against cancer by eliminating damaged cells. However, the accumulation of senescent cells can have long-term detrimental effects and contribute to age-related diseases, including cancer. The role of cellular senescence in cancer is ambiguous and controversial, and its detection and study in cancer patients present challenges. This review highlights the methods and challenges of detecting cellular senescence in cancer patients, and discusses its prognostic implications.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Chemistry, Multidisciplinary
Yujian Zou, Yufei Wang, Xiaohong Wen, Chihao Li, Lei Lei, Qiuping Guo, Guoming Sun, Li Yu, Hemin Nie
Summary: This study reports for the first time that FN is the target protein of aptamer ZY-1 and explores the mechanism of ZY-1 binding to cFN. The specific binding of ZY-1 to cFN and its sensitivity in detecting tumors are validated through in vitro assay and noninvasive in vivo fluorescence imaging. A proof-of-concept study further proves the ZY-1-mediated targeted cancer therapy using a ZY-1-based complex loaded with Dox. This study would facilitate more comprehensive studies of anti-FN aptamers in the imaging and treatment of tumors and other FN-associated diseases.
ADVANCED FUNCTIONAL MATERIALS
(2022)
Article
Cell Biology
Kathryn Davidson, Paul Grevitt, Maria F. Contreras-Gerenas, Katherine S. Bridge, Miguel Hermida, Kunal M. Shah, Faraz K. Mardakheh, Mark Stubbs, Rosemary Burke, Pedro Casado, Pedro R. Cutillas, Sarah A. Martin, Tyson Sharp
Summary: The loss of the tumour suppressor gene LIMD1 is an early event in lung oncogenesis, affecting approximately 45% of non-small cell lung cancers. A drug repurposing screen identified PF-477736 as selectively targeting LIMD1-deficient cells, inducing cell death through apoptosis. PF-477736 showed effectiveness in treating LIMD1(-/-) tumors in xenograft models, presenting a potential new therapeutic subgroup for critical unmet needs.
CELL DEATH & DISEASE
(2021)
Article
Engineering, Biomedical
Bin Xu, Fanjun Zeng, Jialong Deng, Lintong Yao, Shengbo Liu, Hengliang Hou, Yucheng Huang, Hongyuan Zhu, Shaowei Wu, Qiaxuan Li, Weijie Zhan, Hongrui Qiu, Huili Wang, Yundong Li, Xianzhu Yang, Ziyang Cao, Yu Zhang, Haiyu Zhou
Summary: This study developed a biomimetic nanoparticle (CMNP@Osi) that combines membrane-mediated homologous and molecular targeting for enhanced drug delivery. This dual-targeting strategy improved the efficacy of osimertinib, a tyrosine kinase inhibitor used in the treatment of non-small cell lung cancer.
BIOACTIVE MATERIALS
(2023)
Article
Pharmacology & Pharmacy
Fang Li, Chengqiong Mao, Stacy Yeh, Yao Sun, Junbo Xin, Qin Shi, Xin Ming
Summary: This study demonstrates that the anti-MRP1 antibody (Mab)-IR700 conjugate shows higher cellular delivery in multidrug resistant SCLC cells, leading to a stronger photokilling effect and tumor suppression.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2021)
Review
Cell Biology
Aleksandra Danczak-Pazdrowska, Justyna Gornowicz-Porowska, Adriana Polanska, Violetta Krajka-Kuzniak, Maciej Stawny, Aleksandra Gostynska, Blazej Rubis, Sarah Nourredine, Sarah Ashiqueali, Augusto Schneider, Tamara Tchkonia, Saranya P. P. Wyles, James L. L. Kirkland, Michal M. M. Masternak
Summary: This review discusses various aspects of cellular senescence in human skin, including physiology, pathology, and signaling pathways. Cellular senescence can have both beneficial and detrimental effects on the skin, indicating the need for both pro-senescent and anti-senescent therapies depending on the context. Understanding the molecular mechanisms of skin cellular senescence may provide insights for developing effective therapeutics for senescence-related skin disorders.
Article
Oncology
Chunyan Gu, Yajun Wang, Lulin Zhang, Li Qiao, Shanliang Sun, Miaomiao Shao, Xiaozhu Tang, Pinggang Ding, Chao Tang, Yuhao Cao, Yanyan Zhou, Mengjie Guo, Rongfang Wei, Nianguang Li, Yibei Xiao, Jinao Duan, Ye Yang
Summary: The study found that AHSA1 expression was increased in multiple myeloma samples, which was significantly associated with disease relapse and poor prognosis. Additionally, AHSA1 played a role in promoting MM cell proliferation and proteasome inhibitor (PI) resistance. Bufalin and KU-177, as selective inhibitors of AHSA1, may be promising targets for treating MM cell proliferation and proteasome inhibitor resistance.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Yijiang Shi, Fumou Sun, Yan Cheng, Brent Holmes, Binod Dhakal, Joseph F. Gera, Siegfried Janz, Alan Lichtenstein
Summary: This study investigates the role of A1-dependent myc IRES translation in multiple myeloma and finds a positive feedback loop between A1 and c-myc. The J007 inhibitor, which disrupts the interaction between A1 and the myc IRES, decreases myc translation and expression, and inhibits tumor growth. These findings highlight the critical importance of A1-dependent myc IRES translation in multiple myeloma.
MOLECULAR CANCER THERAPEUTICS
(2022)
Article
Biochemistry & Molecular Biology
Zhen Hua, Rongfang Wei, Mengjie Guo, Zigen Lin, Xichao Yu, Xinying Li, Chunyan Gu, Ye Yang
Summary: This study highlights the role of the YTHDF2/STAT5A/MAP2K2/p-ERK axis in the proliferation of multiple myeloma (MM), and targeting YTHDF2 may be a promising therapeutic strategy.
Article
Pharmacology & Pharmacy
Rongfang Wei, Xing Cui, Jie Min, Zigen Lin, Yanyan Zhou, Mengjie Guo, Xiaojuan An, Hao Liu, Siegfried Janz, Chunyan Gu, Hongbo Wang, Ye Yang
Summary: This study found that NAT10 is significantly upregulated in multiple myeloma (MM) patients and is closely associated with poor prognosis. Enforced expression of NAT10 promotes MM growth, while its knockdown reverses these effects. Further investigation revealed CEP170 as an important downstream target of NAT10. These findings suggest that NAT10 may serve as a promising therapeutic target in MM.
ACTA PHARMACEUTICA SINICA B
(2022)
Letter
Hematology
Meera Mohan, Lisa E. Rein, Nishanth Thalambedu, Yetunde Ogunsesan, Munawwar Hussain, Jaskirat Sethi, Fatima Khan, Sravani Gundarlapalli, Lakshmi Yarlagadda, Binod Dhakal, Mary Price, Megan Shirey, Davie Warner, Sharmilan Thanendrarajan, Siegfried Janz, Sabarinath Venniyil Radhakrishnan, Samer Al Hadidi, Aniko Szabo, Anita D'Souza, Maurizio Zangari, Frits van Rhee, Saurabh Chhabra, Carolina Schinke
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Ruchi Sharma, Carol J. Holman, Kyle E. Brown
Summary: SCA is a form of acquired non-autoimmune hemolytic anemia that occurs in advanced liver disease. It is characterized by the presence of acanthocytes or spur cells, which leads to anemia unresponsive to transfusion. Recent studies have shown the existence of a milder form of SCA associated with hemolysis and poor outcomes. The conventional understanding of SCA's pathogenesis is based on limited studies, and further research is needed to develop effective therapies.
ANNALS OF HEPATOLOGY
(2023)
Meeting Abstract
Hematology
Samer Al Hadidi, Aniko Szabo, Jean Esselmann, Lindsay Hammons, Munawwar Hussain, Yetunde Ogunsesan, Nishanth Thalambedu, Fatima Khan, Jaskirat Sethi, Abhishek Janardan, Sabarinath Radhakrishnan, Sharmilan Thanendrarajan, Carolina Schinke, Binod Dhakal, Siegfried Janz, Saurabh Chhabra, Anita D'Souza, Maurizio Zangari, Frits van Rhee, Meera Mohan
Letter
Biophysics
Anita D'Souza, Ruta Brazauskas, Bi Qing Teng, Grant Yun, Hannah Uttley, Jing Dong, Michael B. Dwinell, Marcelo C. Pasquini, Sergio Giralt, Heather Landau, Edward Stadtmauer, Amrita Krishnan, Siegfried Janz
BONE MARROW TRANSPLANTATION
(2023)
Letter
Biophysics
Samer Al Hadidi, Aniko Szabo, Jean Esselmann, Lindsay Hammons, Munawwar Hussain, Yetunde Ogunsesan, Nishanth Thalambedu, Fatima Khan, Jaskirat Sethi, Abhishek Janardan, Sabarinath Venniyil Radhakrishnan, Sharmilan Thanendrarajan, Carolina Schinke, Binod Dhakal, Siegfried Janz, Saurabh Chhabra, Anita D'Souza, Maurizio Zangari, Frits van Rhee, Meera Mohan
BONE MARROW TRANSPLANTATION
(2023)
Letter
Hematology
Ariel Kleman, Arun Singavi, Lauren Pommert, Angela J. Mathison, Parameswaran Hari, Binod Dhakal, Meera Mohan, Siegfried Janz, Jennifer M. Knight, Mithun Shah, Carolina Schinke, Robert Burns, George Francis Steinhardt, Sridhar Rao, Karen Carlson
Article
Pathology
Saurav Chopra, Nitin J. Karandikar, Carol J. Holman
Summary: This study evaluated and compared the peripheral blood findings in patients with acute COVID-19 and other viral respiratory infections. The most common peripheral blood abnormalities in COVID-19 patients were anemia, thrombocytopenia, absolute lymphopenia, and reactive lymphocytes. Other viral respiratory infections were associated with specific peripheral blood findings, including low red blood cell count, low hematocrit, high mean corpuscular volume, thrombocytopenia, low mean platelet volume, high red cell distribution width, band neutrophilia, and toxic granulation in neutrophils.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
(2023)
Letter
Biophysics
Meera Mohan, Siegfried Janz, Ruta Brazauskas, Michael B. Dwinell, Bi Qing Teng, Grant Yun, Jing Dong, Marcelo C. Pasquini, Sergio Giralt, Heather Landau, Edward Stadtmauer, Amrita Krishnan, Anita D'Souza
BONE MARROW TRANSPLANTATION
(2023)
Review
Oncology
Yiwen Zhang, Lu Lu, Feifeng Song, Xiaozhou Zou, Yujia Liu, Xiaowei Zheng, Jinjun Qian, Chunyan Gu, Ping Huang, Ye Yang
Summary: Non-protein target drugs, especially RNA-based gene therapies, have gained global recognition for treating hereditary diseases. However, there is a lack of miracle drugs for cancer, which remains a challenging condition. As biopharmaceutical research advances, the focus of cancer therapy has shifted towards non-protein targets, particularly RNA therapeutics such as oligonucleotide drugs and mRNA vaccines. This review provides a summary of the clinical research progress in RNA therapeutics, emphasizing the importance of appropriate target selection and optimized delivery vehicles in enhancing the effectiveness of cancer treatment in vivo.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2023)
Letter
Biophysics
Meera Mohan, Anai Kothari, Nathaniel Verhagen, Aditya Shreenivas, Sabarinath Venniyil Radhakrishnan, Binod Dhakal, Carlos Figueroa-Castro, Saurabh Chhabra, Siegfried Janz, Marcello Pasquini, Mehdi Hamadani, Aniko Szabo, Anita D'Souza
BONE MARROW TRANSPLANTATION
(2023)
Letter
Oncology
Fumou Sun, Yan Cheng, Jun Ying, David Mery, Samer Al Hadidi, Visanu Wanchai, Eric R. Siegel, Hongwei Xu, Dongzheng Gai, Timothy Cody Ashby, Clyde Bailey, Jin-Ran Chen, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Siegfried Janz, Bart Barlogie, Frits Van Rhee, Guido Tricot, John D. Shaughnessy Jr, Fenghuang Zhan
Summary: Researchers used gene expression profiling to stratify the risk of MGUS and developed an optimized signature based on large samples and long-term follow-up. This signature accurately predicted MGUS progression and provided guidance for the management of MGUS patients.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)